Show simple item record

dc.contributor.authorDrewett, L.
dc.contributor.authorPinilla, K. A.
dc.contributor.authorGrybowicz, L.
dc.contributor.authorWulff, J.
dc.contributor.authorDayimu, A.
dc.contributor.authorDemiris, N.
dc.contributor.authorLucey, R.
dc.contributor.authorVallier, A. L.
dc.contributor.authorQian, W. D.
dc.contributor.authorMachin, A.
dc.contributor.authorMcAdam, K.
dc.contributor.authorRoylance, R.
dc.contributor.authorCopson, E. R.
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorLevitt, N.
dc.contributor.authorProvenzano, E.
dc.contributor.authorTischkowitz, M.
dc.contributor.authorMcMurtry, E.
dc.contributor.authorEarl, H.
dc.contributor.authorAbraham, J. E.
dc.date.accessioned2023-05-17T09:50:51Z
dc.date.available2023-05-17T09:50:51Z
dc.date.issued2022en
dc.identifier.citationDrewett L, Pinilla KA, Grybowicz L, Wulff J, Dayimu A, Demiris N, et al. Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509500082.en
dc.identifier.doi10.1158/1538-7445.AM2022-CT562en
dc.identifier.urihttp://hdl.handle.net/10541/626258
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2022-CT562en
dc.titlePARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patientsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridgeen
dc.identifier.journalCancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record